rss
J Clin Pathol 2005;58:640-644 doi:10.1136/jcp.2004.022509
  • Original article

BRAF and NRAS mutations are uncommon in melanomas arising in diverse internal organs

  1. C W Wong1,
  2. Y S Fan1,
  3. T L Chan1,
  4. A S W Chan1,
  5. L C Ho2,
  6. T K F Ma3,
  7. the Cancer Genome Project4,
  8. S T Yuen1,
  9. S Y Leung1
  1. 1Department of Pathology, University of Hong Kong, Queen Mary Hospital, Hong Kong
  2. 2Department of Pathology, Queen Elizabeth Hospital, Hong Kong
  3. 3Department of Pathology, Alice Ho Mui Ling Nethersole Hospital, Hong Kong
  4. 4Cancer Genome Project, The Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton CB10 1SA, UK
  1. Correspondence to:
 Dr S Y Leung
 Department of Pathology, The University of Hong Kong, Queen Mary Hospital, Hong Kong; suetyihkucc.hku.hk
  • Accepted 9 November 2004

Abstract

Background: Malignant melanoma arising from different body compartments may be associated with differing aetiological factors and clinical behaviour, and may manifest diverse molecular genetic profiles. Although many studies have focused on cutaneous melanoma, little is known of mucosal and other types of melanoma. In particular, malignant melanoma of soft parts is different from other melanomas in many respects, yet manifests a common melanocytic differentiation. Mutation of BRAF is now known to be common in cutaneous melanomas, and raises possible new therapeutic options of anti-RAF treatment for these patients. Few data are available for non-cutaneous melanomas.

Aims: To study the incidence of BRAF and NRAS mutations in melanomas arising in diverse internal organs.

Methods: Fifty one melanomas from various internal organs were investigated for BRAF and NRAS mutation by direct DNA sequencing.

Results: BRAF and NRAS mutations were found in two and five mucosal melanomas arising from the aerodigestive and female genital tracts (n = 36). Their occurrence is mutually exclusive, giving a combined mutation incidence rate of 19.4% in mucosal melanomas. Both BRAF and NRAS mutations were absent in malignant melanoma of soft parts (n = 7). BRAF mutation was also absent in uveal melanoma (n = 6), but was seen in two of five cutaneous melanomas. The incidence of BRAF or combined BRAF/NRAS mutations in all non-cutaneous groups was significantly lower than published rates for cutaneous melanomas.

Conclusion: Each melanoma subtype may have a unique oncogenetic pathway of tumour development, and only a small fraction of non-cutaneous melanomas may benefit from anti-RAF treatment.

Footnotes

  • Competing interest: Members of the Cancer Genome Project are inventors of a patent relating to the development of BRAF for treatment and diagnostics

Latest from JCP Education

Latest from JCP Education

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JCP.
View free sample issue >>

Free archive
The full back archive is now available for JCP. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest Pathology jobs

    Latest Pathology jobs